Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
NOVATO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended September 30, 2023 and provided its financial guidance for the year.
- For the full year 2023, the company expects:
Crysvita revenue in the range of $325 million to $340 million. - This includes all regions where Ultragenyx will recognize revenue, including the royalties in Europe, which have been ongoing, and the royalties in North America, which began in April 2023.
- In May 2023, Ultragenyx announced the last patient had been dosed in the Phase 3 study.
- ET to discuss the third quarter 2023 financial results and provide a corporate update.